CN Patent

CN120098993A — 一种新型的双链siRNA、其缀合物及其用途

Assigned to Guangdong HEC Pharmaceutical Co Ltd · Expires 2025-06-06 · 1y expired

What this patent protects

本发明提供了一种新型的双链siRNA、其缀合物及其用途，其中，所述双链siRNA及其缀合物可以抑制LAP基因表达，可制备用于治疗和/或预防LAP相关疾病的药物。

USPTO Abstract

本发明提供了一种新型的双链siRNA、其缀合物及其用途，其中，所述双链siRNA及其缀合物可以抑制LAP基因表达，可制备用于治疗和/或预防LAP相关疾病的药物。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN120098993A
Jurisdiction: CN
Classification: —
Expires: 2025-06-06
Drug substance claim: No
Drug product claim: No
Assignee: Guangdong HEC Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.